期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

雌激素受体β的表达对乳腺癌细胞体内致瘤能力的影响 被引量：2

Effects on xenografts in nude mice of estrogen receptor β expression
原文传递
导出
摘要 目的 观察雌激素受体β（ERβ）的表达对乳腺癌细胞生物学特性以及裸鼠体内致瘤力的影响,探讨其在乳腺癌发生发展中的作用.方法 通过小干扰RNA（siRNA）的方法将ERβ高表达的MCF-7细胞敲降ERβ基因,筛选稳定表达株,利用裸鼠进行体内成瘤性实验,比较肿瘤生长曲线及裸鼠的生存期.结果 siRNA能明显降低乳腺癌细胞MCF-7中ERβ的表达,ERβ被敲降后MCF-7细胞的成瘤能力增强.RNA干扰组在裸鼠皮下接种的第12天开始可触摸到实体肿瘤的形成,对照组第27天开始可触摸到实体肿瘤的形成.RNA干扰组8只裸鼠中位生存时间为33d,对照组8只裸鼠中位生存时间为66 d.结论 ERβ基因对人乳腺癌细胞MCF-7在裸鼠体内皮下成瘤能力有明显的抑制作用. Objective This study was to investigate the effect of estrogen receptor β （ERβ） on tumorigenesis of human breast cancer cell line in nude mice.Methods Breast cancer cell line MCF-7 （high expression of ERβ） was chose to show the tumorigenesis ablity after silence ERβ by small interfering RNA （siRNA）.Results siRNA-ERβcan decrease the expression of ERβprotein in MCF-7 cells effectively.After silence ERββby siRNA,the tumorigenesis of MCF-7 cell were significantly enhanced.In ERβ-siRNA group,the tumor was papable on the 12th day,while in control-RNA group,the tumor was papable on the 27th day.The median survival time was 33 days in ERβ-siRNA group and 66 days in control-RNA group.Conclusion The ERβ gene can diminished the xenografts of MCF-7 cells in nudemice obviously.
作者 刘瑞磊 刘宇 张鹏 黄勇 汤谧 李玺 赖远辉
机构地区 中山大学附属第三医院甲乳外科 中山大学附属第三医院岭南医院普外科 中山大学附属第一医院东院外一科
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第8期1700-1701,共2页 Chinese Journal of Experimental Surgery
基金 广东省医学科研基金资助项目（A2011183）
关键词 雌激素受体Β 乳腺癌 小干扰RNA 裸鼠 Estrogen receptor β Breast cancer Small interfering RNA Nude mice
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1王晓稼,郑树,彭佳萍,吴金民.乳腺癌患者ST13、Hsp70、pS2、雌激素受体和孕激素受体表达及其与生存的关系[J].中华实验外科杂志,2005,22(9):1071-1073. 被引量：7
  • 2Gustafsson JA,Warner M.Estrogen receptor beta in the breast:role in estrogen responsiveness and development of breast cancer[J].J Steroid Biochem Mol Biol,2000,74 (5):245-248.
  • 3Kapila K,Anim JT,Francis IM,et al.Expression of estrogen receptor alpha and estrogen receptor beta in fine needle aspirates of breast carcinoma[J].Acta Cytol,2010,54(1):25-30.
  • 4Fox EM,Davis RJ,Shupnik MA.ERbeta in breast cancer——onlooker,passive player,or active protector[J].Steroids,2008,73 (11):1039-1051.
  • 5孙慧,张静,战忠利,郝希山.雌激素受体-β与其信号传导通路中相关基因在不同乳腺癌模型发展中的作用机制[J].中华实验外科杂志,2006,23(11):1422-1423. 被引量：8
  • 6Eshun FK,Currier MA,Gillespie RA,et al.VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy[J].Gene Ther,2010,17 (7):922-929.
  • 7Renoir JM,Marsaud V,Lazennec G.Estrogen receptor signaling as a target for novel breast cancer therapeutics[J].Biochem Pharmacol,2013,85 (4):449-465.
  • 8Dwyer MA,Joseph JD,Wade HE,et al.WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration[J].Cancer Res,2010,70(22):9298-9308.

二级参考文献12

  • 1Ruibal A, Arias JI, Del Rio MC, et al. Histological grade in breast cancer:association with clinical and biological features in a series of 229 patients. Int J Biol Markers, 2001, 16:56-61.
  • 2Gaci Z, Bouin-Pineau MH, Gaci M, et al. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors. Int J Oncol, 2001, 18:793-800.
  • 3Tamargo F, Vizoso F, Lamelas M. Analysis of the cytosolic content of the pS2 protein in breast cancer. Rev Esp Med Nucl, 2002, 21:28-33.
  • 4Looi LM, Azura WW, Cheah PL, et al. pS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status. Pathology, 2001,33:283-286.
  • 5Surowiak P, Dziegiel P, Zabel M, et al. Analysis of estrogen receptor(ER) and estrogen-dependent pS2 protein expression in ceils of mammary ductal carcinoma. Folia Histochem Cytobiol, 2001, 39 : 141-142.
  • 6Ruibal A, Arias J, Del Rio MC, et al. Infiltrating ductal carcinomas of the breast in women over 60 years of age. Association with higher cellular proliferation and lower PS2, cell surface and cytosolic hyaluronic acid concentrations. Rev Esp Med Nucl, 2001,20:525-529.
  • 7Montgomery DL, Morimoto R1, Gierasch LM. Mutations in the substrate binding domain of the Escherlchia coli 70 kDa molecular chaperone, DnaK, which alter substrate affinity or interdomain coupling. J Mol Biol, 1999, 286:915-932.
  • 8Chen S, Prapapanich V, Rimerman RA, et al. Interactions of p60, a mediator of progesterone receptor assembly, with heat shock proteins Hsp90 and Hsp70. Mol Endocrinol, 1996, 10:682-693.
  • 9Johnson J, Corbisier R, Stensgard B, et al. The involvement of p23,Hsp90, and immunophilins in the assembly of progesterone receptor complexes. J Steroid Biochem Mol Biol, 1996, 56 : 31-37.
  • 10Ciocca DR, Green S, Elledge RM, et al. Heat shock proteins Hsp27 and Hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer( a Southwest Oncology Group Study). Clin Cancer Res, 1998, 4 : 1263-1266.

共引文献13

同被引文献21

  • 1孙慧,张静,战忠利,郝希山.雌激素受体-β与其信号传导通路中相关基因在不同乳腺癌模型发展中的作用机制[J].中华实验外科杂志,2006,23(11):1422-1423. 被引量：8
  • 2E. A. Dubil, W. Bshara, K. O. Odunsi, et al. Emerging pathw- ays in treating human epidermal growth factor receptor- 2- negative breast cancer [ J ]. New Horizons in Translational Medicine, 2015, 2 (2): 27-28.
  • 3Kim IS, Jeong SJ, Kim SH, et al. Special AT-rich sequence- binding protein 2 and its related genes play key roles in the dif- ferentiation of MC333-E1 osteoblast like cells [ J]. Biochem Biophys Res Commun, 2012, 417 (2) : 697-703.
  • 4Dubil EA, Bshara W, Odunsi KO, et al. Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain- containing protein 1A are rare, drug - resistant, and deadly [ J]. Gynecol Oncol; 2014, 133 (1): 114-115.
  • 5Idelman G, Jacobson EM, Tuttle TR, et al. Lactogens and estrogens in breast cancer chemoresistance [ J ]. Expert Rev Endocrinol Metab, 2011,6(3) :411-422.
  • 6Ma CX. Estrogen and progesterone receptors in breast cancer[ J 1- Clin Adv Hematol Onco1,2011,9 (5) :385-386.
  • 7Renoir JM, Marsaud V, Lazennec G. Estrogen receptor signaling as a target for novel breast cancer therapeutics [ J ]. Biochem Pharmacol, 2013,85 (4) :449-465.
  • 8Dwyer MA ,Joseph JD, Wade HE, et al. WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an au- tocrine manner to increase cancer cell migration [ J ]. Cancer Res, 2010,70(22) :9298-9308.
  • 9Grober OM, Mutarelli M, Giurato G, et al. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an exten- sive interplay with estrogen receptor alpha for target gene regulation [ J ]. BMC Genomics ,2011,12:36.
  • 10Chen L, Qiu J, Yang C, et al. Identification of a novel estrogen recep- tor betal binding partner, inhibitor of differentiation-l, and role of ERbetal in human breast cancer cells [ J 1. Cancer Lett, 2009,278 (2) :210-219.

引证文献2

二级引证文献5

中华实验外科杂志
2014年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部